Skip to main content

Opterion Health secures investment of 6.5 million Swiss francs

| News

Opterion Health secures investment of 6.5 million Swiss francs


Opterion Health has raised a total of 6.5 million Swiss francs as part of a financing round. The company, which is headquartered in Muttenz in the canton of Basel-Landschaft, won over investors with its innovative peritoneal dialysis solution. Preparations are now underway for the start of a Phase I clinical trial.

Opterion Health AG has now closed a financing round that was oversubscribed by 60 percent. According to a press release, the company managed to successfully secure investment totaling 6.5 million Swiss francs. As part of the financing round, additional option capital in the amount of 7.3 million Swiss francs was also issued. Both existing and new private and institutional investors participated in the financing round.

Opterion Health is developing a solution for an innovative peritoneal dialysis (PD) solution. According to information from the company itself, the solution is set to “revolutionize” the dialysis market by replacing the gold standard of the current market leader. At present, the solution is still in the preclinical phase. However, the fresh capital should now help to accelerate the process so that a Phase I clinical trial can begin sooner than originally expected.

Settlement supported by Basel Area Business & Innovation

In addition to closing the financing round, Opterion Health has also announced a change in personnel. In this context, Stefan Wohlfeil has resigned his seat on the Board of Directors in order to enter retirement. Shareholders have now elected Jan-Anders Karlsson and Robert Leitz as new members of the Board of Directors. The two newcomers will bring many years of experience in the areas of life sciences and finance to the company.

In 2021, Opterion Health moved its headquarters to Muttenz in the canton of Basel-Landschaft, with the aim of exploiting the region’s life sciences ecosystem. In so doing, the company was supported by the investment and innovation promotion agency Basel Area Business & Innovation.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.